Sihuan Pharmaceutical's Semaglutide Injection Advances Through Chinese Regulatory Pipeline with Marketing Application Acceptance
核心洞察
Sihuan Pharmaceutical's subsidiary Huisheng Biopharmaceutical (搜索) received NMPA acceptance for semaglutide injection marketing application to treat type 2 diabetes (搜索) in adults.
The once-weekly GLP-1 receptor (搜索) agonist has completed Phase III clinical enrollment for weight loss indication and is currently in follow-up stage.
Semaglutide injection previously obtained clinical trial approval from NMPA in July 2023, marking significant progress in China's diabetes treatment landscape.
Sihuan Pharmaceutical Holdings Group (搜索) Ltd. has achieved a significant regulatory milestone as China's National Medical Products Administration (搜索) (NMPA) accepted the marketing application for semaglutide injection developed by its non-wholly owned subsidiary, Huisheng Biopharmaceutical (搜索) Co., Ltd. The application seeks approval for improving glycemic control in adults with type 2 diabetes (搜索).
The acceptance represents substantial progress from the initial clinical trial approval granted by NMPA in July 2023. According to the company, the weight loss indication for semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage, indicating the drug's potential for dual therapeutic applications.
GLP-1 Receptor Agonist Mechanism and Clinical Benefits
Semaglutide injection functions as a long-acting GLP-1 receptor (搜索) agonist (GLP-1RA) administered once weekly. The drug enhances insulin secretion in a glucose-dependent manner by activating GLP-1 receptors, suppresses glucagon secretion, and delays gastric emptying to reduce blood sugar levels. Additionally, semaglutide reduces appetite and decreases food intake, helping patients lower caloric consumption and achieve weight loss.
The therapeutic profile extends beyond glucose control, with the potential to significantly reduce weight, lower blood pressure, improve lipid profiles, and reduce the risk of major cardiovascular adverse events. These comprehensive benefits increase patient compliance and improve quality of life compared to classic GLP-1 receptor (搜索) agonist drugs like liraglutide.
Market Context and Commercial Potential
Semaglutide injection was first launched in the United States in December 2017, and by 2022, global sales exceeded US$10 billion. The drug received approval for entry into the Chinese market in 2021 and was included in the national medical insurance catalogue the same year. Sales in the Greater China region reached US$311 million in 2022, demonstrating explosive growth potential.
The Chinese diabetes market presents substantial opportunities, with approximately 140 million diabetes patients currently in the country. The drug is recommended for use in patients with type 2 diabetes (搜索) mellitus, cardiovascular disease (搜索), or patients at very high cardiovascular risk.
Strategic Significance for Huisheng Biopharmaceutical
Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Holdings Group (搜索), commented that the clinical trial approval "will help the Group to further strengthen the provision of providing diabetic patients with a full range of comprehensive and integrated treatment solutions for the diabetic patients."
The acceptance of the marketing application represents another significant advancement in the development process, positioning the drug to enhance the core competitiveness of both Sihuan Pharmaceutical and Huisheng Biopharmaceutical (搜索) in the diabetes treatment field. Huisheng Biopharmaceutical has stated its commitment to becoming a leading biopharmaceutical company with comprehensive product coverage in diabetes and complications within China.
Complementary Pipeline Development
Alongside semaglutide development, Huisheng Biopharmaceutical (搜索) recently obtained drug registration approval from NMPA for Thioctic Acid Injection (搜索), a peripheral neuropathy (搜索) drug deemed to have passed consistency evaluation on quality and efficacy of generic drugs. This approval demonstrates the company's broader strategy for comprehensive diabetes care, as diabetic peripheral neuropathy (搜索) affects more than 50% of diabetes patients in China.